Nuvation Bio Inc. Deferred Revenue Recognized
Nuvation Bio Inc. (NUVB) reported Deferred Revenue Recognized of $2.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06
- Nuvation Bio Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $700.00K.
- Nuvation Bio Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $700.00K.
- Nuvation Bio Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-06-30 was $1.30M.
- Nuvation Bio Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $8.30M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.60M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $8.30M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $6.70M 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $9.70M 10-Q · filed 2025-08-07 | |||
| 2024-09-30 | $700.00K 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |